Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers

被引：9
作者：
Berl, Tomas [1 ]
机构：
[1] Univ Colorado Hlth Sci, Div Nephrol, Denver, CO 80262 USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2008年 / 23卷 / 08期
关键词：
D O I：
10.1093/ndt/gfn239
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：2443 / 2447
页数：5
相关论文
共 26 条
[21]   Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria [J].
Rossing, K ;
Schjoedt, KJ ;
Jensen, BR ;
Boomsma, F ;
Parving, HH .
KIDNEY INTERNATIONAL, 2005, 68 (03) :1190-1198
[22]   Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy - A double-blind randomized cross-over study [J].
Rossing, K ;
Christensen, PK ;
Hansen, BV ;
Carstensen, B ;
Parving, HH .
DIABETES CARE, 2003, 26 (01) :150-155
[23]   Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies [J].
Ruggenenti, P ;
Mise, N ;
Pisoni, R ;
Arnoldi, F ;
Pezzotta, A ;
Perna, A ;
Cattaneo, D ;
Remuzzi, G .
CIRCULATION, 2003, 107 (04) :586-592
[24]  
SCHJOEDT KJ, 2007, P EUR ASS STUD DIAB
[25]   Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study [J].
Schmieder, RE ;
Klingbeil, AU ;
Fleischmann, EH ;
Veelken, R ;
Delles, C .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (10) :3038-3045
[26]   Telmisartan, ramipril, or both in patients at high risk for vascular events [J].
Yusuf, Salim ;
Teo, Koon K. ;
Pogue, Janice ;
Dyal, Leanne ;
Copland, Ingrid ;
Schumacher, Helmut ;
Ingelheim, Boehringer ;
Dagenais, Gilles ;
Sleight, Peter ;
Anderson, Craig .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) :1547-1559
123